|
embryofoetopathie door methimazol (aandoening)
embryofoetopathie door methimazol
Methimazole embryofetopathy
Embryofetopathy caused by methimazole
A teratogenic embryofetopathy that results from maternal exposition to methimazole in the first trimester of pregnancy. Methimazole is an antithyroid thionamide drug used for the treatment of Graves' disease. In the infant, methimazole may result in choanal atresia, esophageal atresia, omphalocele, omphalomesenteric duct anomalies, congenital heart disease (such as ventricular septal defect), renal system malformations and aplasia cutis. Additional features that may be observed include facial dysmorphism (short up slanting palpebral fissures, a broad nasal bridge with a small nose and a broad forehead) and athelia.
Id724144006
StatusPrimitive
Associated morphologymorfologische afwijking
Causative agentthiamazol
Finding sitestructuur van foetus
Occurrencecongenitaal
Pathological processproces van pathologische ontwikkeling
DHD Diagnosis thesaurus reference set
RIVM authorized national diagnosis thesaurus to ICD10 complex mapping reference set
TargetQ86.8
TermOverige congenitale gestoorde-ontwikkelingssyndromen door bekende exogene oorzaken
SNOMED CT to Orphanet simple map1923
SNOMED CT to ICD-10 extended map
TargetQ86.8
RuleTRUE
AdviceALWAYS Q86.8
CorrelationSNOMED CT source code to target map code correlation not specified